Table 3.
Risk of hip fracture in different subgroups.
| Non-Users | Aspirin Monotherapy | Clopidogrel Monotherapy | Dual Antiplatelet Therapy | ||||
|---|---|---|---|---|---|---|---|
| Variables | aHR (95% CI) | p-Value | aHR (95% CI) | p-Value | aHR (95% CI) | p-Value | |
| Sex | |||||||
| Female | 1.00 | 1.21 (1.06, 1.37) | 0.004 | 1.03 (0.77, 1.39) | 0.838 | 0.99 (0.68, 1.43) | 0.958 |
| Male | 1.00 | 1.05 (0.81, 1.11) | 0.522 | 1.03 (0.78, 1.35) | 0.860 | 0.69 (0.48, 1.01) | 0.057 |
| Age | |||||||
| <30 | 1.00 | 2.09 (0.74, 5.89) | 0.165 | ||||
| 30–50 | 1.00 | 0.92 (0.65, 1.29) | 0.614 | 1.08 (0.39, 2.96) | 0.886 | 0.88 (0.32, 2.38) | 0.798 |
| 50–70 | 1.00 | 1.07 (0.91, 1.24) | 0.412 | 0.91 (0.61, 1.36) | 0.657 | 0.95 (0.64, 1.42) | 0.815 |
| >70 | 1.00 | 1.02 (0.89, 1.17) | 0.777 | 1.11 (0.87, 1.41) | 0.390 | 0.70 (0.87, 1.41) | 0.059 |
| CCIs | |||||||
| 0 | 1.00 | 1.14 (0.99, 1.31) | 0.065 | 0.84 (0.47, 1.49) | 0.551 | 0.67 (0.38, 1.18) | 0.165 |
| 1 | 1.00 | 0.97 (0.78, 1.22) | 0.824 | 1.01 (0.66, 1.55) | 0.952 | 1.08 (0.70, 1.65) | 0.735 |
| 2 | 1.00 | 0.94 (0.73, 1.21) | 0.629 | 0.98 (0.63, 1.52) | 0.913 | 0.49 (0.23, 1.04) | 0.064 |
| ≥3 | 1.00 | 1.10 (0.86, 1.40) | 0.439 | 1.11 (0.82, 1.51) | 0.498 | 0.84 (0.51, 1.39) | 0.506 |
| aDCSI | |||||||
| 0 | 1.00 | 1.08 (0.97, 1.20) | 0.177 | 1.02 (0.80, 1.31) | 0.853 | 0.77 (0.57, 1.05) | 0.094 |
| 1 | 1.00 | 1.05 (0.75, 1.48) | 0.770 | 0.80 (0.41, 1.57) | 0.518 | 1.25 (0.62, 2.57) | 0.521 |
| ≥2 | 1.00 | 1.17 (0.81, 1.69) | 0.416 | 1.13 (0.74, 1.73) | 0.577 | 0.85 (0.40, 1.80) | 0.665 |
| Osteoporosis | |||||||
| No | 1.00 | 1.05 (0.95, 1.16) | 0.339 | 1.03 (0.84, 1.26) | 0.781 | 0.82 (0.63, 1.07) | 0.139 |
| Yes | 1.00 | 0.62 (0.23, 1.67) | 0.344 | 0.84 (0.11, 6.38) | 0.865 | ||
cHR: crude hazard ratio; aHR: adjusted hazard ratio; 95% CI: 95% confidence interval; CCI: Charlson comorbidity index; aDSCI: adapted diabetes complication severity index.